DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Degn KB, Juhl CB, Sturis J. et al.
One week's treatment with the long-acting glucagon-like peptide 1
derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and
beta-cell function and reduces endogenous glucose release in patients with type
2 diabetes.
Diabetes 2004;
53: 1187-1194
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.